Phase 2 RCT in 144 participants with treatment-resistant depression (142 analysed): psilocybin 25 mg with psychotherapy did not significantly improve week-6 HAMD17 response vs nicotinamide (17.0% vs 10.6%; OR 1.73, P=.19). Dosing-day suicidal ideation was higher (4% vs 1%-2%).
RCTn = 144
Mertens et al. Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial